ArticleCureus2026
Pediatric Lymphoma in Jordan: A Retrospective Single-Center Study of Clinical Presentation, Treatment, and Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric lymphoma, encompassing Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), represents a significant cause of childhood cancer morbidity with limited data available from Middle Eastern settings. This study aims to characterize the clinical presentations, biomarker profiles, treatment patterns, and outcomes of pediatric HL and NHL at a tertiary care center in Jordan.
methodsThis retrospective study included children aged 0-16 years diagnosed with HL or NHL at Queen Rania Children's Hospital in Jordan from 2015 to 2024. Data were collected on demographics, clinical presentation, laboratory markers, treatment regimens, and outcomes. Categorical data were analyzed using chi-square or Fisher's exact tests, continuous variables using Mann-Whitney U tests, and Event-Free Survival (EFS) was assessed using Kaplan-Meier curves.
resultsA total of 49 patients' data were analyzed. The findings indicate a high rate of late-stage diagnosis among pediatric lymphoma patients in Jordan, with 38 (77.5%) presenting at advanced stages. Most NHL cases involved aggressive subtypes, including Burkitt and T-lymphoblastic lymphoma. Compared with HL patients, those with NHL exhibited significantly higher median C-reactive protein (CRP; 78.5 mg/L vs. 12.0 mg/L,
conclusionsPediatric lymphoma in Jordan is most often diagnosed at an advanced stage, particularly NHL. Advanced NHL is associated with increased mortality. Early diagnosis, targeted therapy implementation, and incorporation of biomarkers such as LDH and CRP are urgently needed to improve risk assessment and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.